INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day inc...
Next-generation FDA-cleared medical device brings non-invasive heart and lung disease detection to healthcare professionals at the point of care ...
SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health....
Techsomed Ltd., the developer of BioTrace, an AI powered software platform for real time ablation zone imaging and treatment precision enhancement....
Collaboration Bolsters LianMedical's Mission to Bring Novel Technologies to the Asian Market and Supports Global Expansion of CereVasc's Technology...
Medical AI solutions, including CXR-AID, officially included in Japanese health insurance reimbursement as a management service fee of imaging diagnosis...
Founded in 2014, Packaging Compliance Labs is a leading sterile packaging center of excellence, providing comprehensive healthcare packaging solutions aimed to accelerate medical device and pharmaceutical product launches. PCL's extensive capabilities support customers in each step of packaging from the design phase to full-scale production. ...
Escala Medical Ltd., proudly announces its selection as a recipient of a €5.5 million in grant and equity investment from the European Innovation Council. Escala is at the forefront of the pelvic organ prolapse (POP) treatment revolution....
Medtronic plc(opens new window) (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system. These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting glycemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations, found that the pro...
Revolutionary Initiatives Driving Advancements in Neonatal Care across India...
